Carregant...
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
Although all current antipsychotics act by interfering with the action of dopamine at dopamine D2 receptors, two recent reports showed that 800 to 1000 mg of cannabidiol per day alleviated the signs and symptoms of schizophrenia, although cannabidiol is not known to act on dopamine receptors. Becaus...
Guardat en:
| Publicat a: | Transl Psychiatry |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315552/ https://ncbi.nlm.nih.gov/pubmed/27754480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tp.2016.195 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|